Current and Emerging Clinical Strategies for Pancreatic Cancer Treatment

Join us for this dynamic CME-certified symposium, in which an expert panel will discuss current best practices and emerging strategies for treating patients with pancreatic cancer. Sign up now!

Not an official event of the 2021 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Key considerations for treatment selection, sequencing, and treatment modifications in metastatic pancreatic adenocarcinoma

Selection of adjuvant systemic therapy for patients with resected pancreatic adenocarcinoma

Neoadjuvant chemotherapy regimen selection for resectable or borderline-resectable pancreatic adenocarcinoma

Emerging therapeutic strategies


Date / Time
Event Details


Michael J. Pishvaian, MD

Associate Professor, Department of Oncology
Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
5255 Loughboro Rd NW, Washington, DC 20016, USA

Rachna Shroff, MD

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging therapies into the treatment of patients with pancreatic cancer.

Target Audience
This educational program is intended for medical oncologists, radiation oncologists, surgical oncologists, and other healthcare providers who treat patients with pancreatic cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply individualized treatment strategies for the selection and sequencing of therapies for localized and advanced pancreatic cancer
  • Examine the role of PARP inhibitor maintenance after first-line platinum-based chemotherapy for patients with newly diagnosed pancreatic cancer and a germline BRCA mutation
  • Appraise the rationale and available/emerging data for the use of emerging and investigational therapies (novel chemotherapy platforms, PARP inhibitor, immunotherapy [and immunotherapy-based combinations], stroma-targeting agents, tumor treating fields therapy, and others) and integrate into treatment planning as clinically applicable
  • Incorporate strategies to effectively identify and manage disease-related and treatment-related adverse events to support quality of life and continuation of therapy


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.